Literature DB >> 23714731

A neu view of invasive lobular breast cancer.

Ron Bose1.   

Abstract

Genome sequencing of relapsed, invasive lobular breast cancer identified actionable mutations in 86% of the cases. HER2 alterations occur in 27% of the cases, including 4 cases with activating HER2 mutations and 1 with a novel HER2-GRB7 gene fusion. This fusion links the HER2 tyrosine kinase domain to the GRB7 src homology 2 (SH2) domain. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23714731      PMCID： PMC3700640          DOI： 10.1158/1078-0432.CCR-13-1031

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

Authors:  Heidi Greulich; Bethany Kaplan; Philipp Mertins; Tzu-Hsiu Chen; Kumiko E Tanaka; Cai-Hong Yun; Xiaohong Zhang; Se-Hoon Lee; Jeonghee Cho; Lauren Ambrogio; Rachel Liao; Marcin Imielinski; Shantanu Banerji; Alice H Berger; Michael S Lawrence; Jinghui Zhang; Nam H Pho; Sarah R Walker; Wendy Winckler; Gad Getz; David Frank; William C Hahn; Michael J Eck; D R Mani; Jacob D Jaffe; Steven A Carr; Kwok-Kin Wong; Matthew Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

2.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

Authors:  Shizhen Emily Wang; Archana Narasanna; Marianela Perez-Torres; Bin Xiang; Frederick Y Wu; Seungchan Yang; Graham Carpenter; Adi F Gazdar; Senthil K Muthuswamy; Carlos L Arteaga
Journal:  Cancer Cell       Date:  2006-07       Impact factor: 31.743

3.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Authors:  Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

4.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

5.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.

Authors:  Sohrab P Shah; Ryan D Morin; Jaswinder Khattra; Leah Prentice; Trevor Pugh; Angela Burleigh; Allen Delaney; Karen Gelmon; Ryan Guliany; Janine Senz; Christian Steidl; Robert A Holt; Steven Jones; Mark Sun; Gillian Leung; Richard Moore; Tesa Severson; Greg A Taylor; Andrew E Teschendorff; Kane Tse; Gulisa Turashvili; Richard Varhol; René L Warren; Peter Watson; Yongjun Zhao; Carlos Caldas; David Huntsman; Martin Hirst; Marco A Marra; Samuel Aparicio
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

6.  Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.

Authors:  Jeffrey S Ross; Kai Wang; Christine E Sheehan; Ann B Boguniewicz; Geoff Otto; Sean R Downing; James Sun; Jie He; John A Curran; Siraj Ali; Roman Yelensky; Doron Lipson; Gary Palmer; Vincent A Miller; Philip J Stephens
Journal:  Clin Cancer Res       Date:  2013-04-10       Impact factor: 12.531

7.  Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

Authors:  Rama Krishna Kancha; Nikolas von Bubnoff; Natalie Bartosch; Christian Peschel; Richard A Engh; Justus Duyster
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

8.  The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

Authors:  Britta Weigelt; Felipe C Geyer; Rachael Natrajan; Maria A Lopez-Garcia; Amar S Ahmad; Kay Savage; Bas Kreike; Jorge S Reis-Filho
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

9.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.

Authors:  John D Carpten; Andrew L Faber; Candice Horn; Gregory P Donoho; Stephen L Briggs; Christiane M Robbins; Galen Hostetter; Sophie Boguslawski; Tracy Y Moses; Stephanie Savage; Mark Uhlik; Aimin Lin; Jian Du; Yue-Wei Qian; Douglas J Zeckner; Greg Tucker-Kellogg; Jeffrey Touchman; Ketan Patel; Spyro Mousses; Michael Bittner; Richard Schevitz; Mei-Huei T Lai; Kerry L Blanchard; James E Thomas
Journal:  Nature       Date:  2007-07-04       Impact factor: 69.504

10.  Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.

Authors:  Grazia Arpino; Valerie J Bardou; Gary M Clark; Richard M Elledge
Journal:  Breast Cancer Res       Date:  2004-02-17       Impact factor: 6.466
View more
  1 in total

1.  Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3' Oncogenes from FFPE Bulk RNA Sequencing Data.

Authors:  Elizaveta Rabushko; Maxim Sorokin; Maria Suntsova; Alexander P Seryakov; Denis V Kuzmin; Elena Poddubskaya; Anton A Buzdin
Journal:  Biomedicines       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.